Observational studyBMC geriatrics2026
Feasibility of continuous glucose monitoring in an acute geriatric unit - the GLYCOGER study.
Observational study in BMC geriatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundContinuous glucose monitoring (CGM) enhances glycemic control and reduces hypoglycemia in patients with diabetes, but its use in geriatric inpatients remains limited.
aimTo assess the feasibility in CGM use among patients hospitalized in an acute geriatric unit.
methodsWe conducted a pilot single-center observational study involving patients aged ≥ 75 years with insulin-treated diabetes who met the French national criteria for CGM reimbursement. The primary endpoint was feasibility of CGM, defined as the acceptability and continuation of CGM during hospitalization with ≥ 70% sensor activity. Secondary endpoints included hypoglycemia (< 70 mg/dL), factors associated with hypoglycemia and hyperglycemia (> 180 mg/dL), and the clinical, metabolic, and therapeutic determinants of CGM results.
resultsAmong 52 patients (median age 85.5 years; 50% women), 46 (89%) continued CGM during hospitalization and 40 (77%) achieved ≥ 70% sensor activity. A total of 61 hypoglycemic episodes were recorded (mean 1.2 per patient), none of which were symptomatic. Mean time below range (< 70 mg/dL) was 1.4 ± 2.1%, and mean time above range (> 180 mg/dL) was 31.9 ± 22.4%. Exploratory analyses showed that time above range was positively correlated with bolus (ρ = 0.72, p < 0.001) and total daily insulin doses (ρ = 0.68, p < 0.001). At discharge, 38 of the 41 patients (96.7%) who remained on insulin were prescribed CGM. No device-related serious adverse events were observed.
conclusionsCGM use in an acute geriatric unit was feasible and well tolerated, with a high proportion of analyzable sensor data and limited hypoglycemia. These findings support the integration of CGM into routine inpatient geriatric diabetes care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.